Gun Anker
Haukeland University Hospital
36 Papers
628 Citations
Gun Anker is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 22, co-authored 36 publications. Previous affiliations of Gun Anker include University of Bergen.
Chat about Author
Papers
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
Jonas Bergh,Tom Wiklund,Bjørn Erikstein,Elisabet Lidbrink,Henrik Lindman,Per-Uno Malmström,Pirkko Kellokumpu-Lehtinen,Nils-Olof Bengtsson,Gustaf Söderlund,Gun Anker,Erik Wist,Susanne Ottosson,Eeva Salminen,Per Ljungman,Harald Holte,Jonas Nilsson,Carl Blomqvist,Nils Wilking +17 more
TL;DR: In this article, the authors developed an individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support to improve outcomes in patients with high risk early breast cancer.
266
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
Per Eystein Lønning,Paul Taylor,Gun Anker,Julie Iddon,Liv Wie,Linn-Marie Jørgensen,Olav Mella,Anthony Howell +7 more
TL;DR: The results reveal estrogens administered in high doses may have antitumor effects in breast cancer patients heavily pretreated with endocrine therapy, and represents a valuable alternative to chemotherapy in selected patients.
231
Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen.
TL;DR: It is suggested that the homocysteine‐lowering effect of tamoxifen may contribute to the reduction of cardiovascular mortality observed in patients on adjuvant therapy with tamoxIFen.
119
•Journal Article
Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
TL;DR: It is concluded that this aminoglutethimide-tamoxifen interaction should be taken into account when evaluating the clinical effect of this drug combination relative to monotherapy.
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
Ranjan Chrisanthar,Ranjan Chrisanthar,Stian Knappskog,Stian Knappskog,Erik Løkkevik,Gun Anker,Gun Anker,Bjørn Østenstad,Steinar Lundgren,Elisabet Ognedal Berge,Terje Risberg,Ingvil Mjaaland,Lovise Maehle,Lars Fredrik Engebretsen,Johan R. Lillehaug,Per Eystein Lønning,Per Eystein Lønning +16 more
TL;DR: This study is the first reporting an association between CHEK2 mutations and therapy resistance in human cancers and to document mutations in two genes acting direct up/down-stream to each other to cause therapy failure, emphasizing the need to investigate functional cascades in future studies.